Trevi Therapeutics Secures $162M in April Offering, Extends Cash Runway into 2030

summarizeSummary

Trevi Therapeutics reported Q1 2026 financial results and disclosed a $162 million net proceeds offering in April 2026, significantly extending its cash runway into 2030 to fund ongoing clinical trials.

check_boxKey Events

• Substantial Capital Raise

  On April 16, 2026, the company completed an underwritten offering, issuing 13,340,000 shares (including underwriter option) at $13.00 per share, generating approximately $162 million in net proceeds. This offering represents a significant capital infusion for the company.

• Extended Cash Runway

  The company now projects its existing cash, cash equivalents, and marketable securities will fund operating expenses and capital expenditure requirements into 2030, a substantial extension of its financial stability.

• Increased Net Loss and R&D Expenses

  For Q1 2026, net loss increased to $13.2 million from $10.3 million in Q1 2025, and R&D expenses rose to $9.9 million from $7.8 million, reflecting increased clinical development activities.

• Active Clinical Pipeline

  Trevi Therapeutics plans to initiate two Phase 3 trials for IPF-related chronic cough, a Phase 2b trial for non-IPF ILD-related chronic cough, and a Phase 2b trial for refractory chronic cough in 2026, with topline results expected in 2027-2028.

auto_awesomeAnalysis

This 10-Q filing confirms Trevi Therapeutics' strong financial position following a significant capital raise. The $162 million net proceeds from the April 2026 offering, priced at a slight discount to the current market, substantially extends the company's cash runway into 2030. This funding is critical for a clinical-stage biopharmaceutical company, de-risking its operations and providing capital for multiple planned Phase 3 and Phase 2b clinical trials for Haduvio. While the company reported increased net losses and R&D expenses, these are expected as it advances its drug pipeline. The extended cash runway is a major positive, ensuring the company can pursue its development goals without immediate financing pressures.